Lv3
290 积分 2026-06-22 加入
Bone matters: Ga-68 PSMA PET/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617
12天前
已完结
Predicting hematologic toxicity of lutetium-177 prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer using pretreatment gallium-68 prostate-specific membrane antigen positron emission tomography imaging: preliminary data in Asian patients
12天前
已完结
Prediction of early biochemical response after 177Lu-PSMA radioligand therapy with 68Ga-PSMA PET, a different perspective with quantitative parameters
12天前
已完结
Outcome of 177Lu-PSMA Radionuclide Treatment in Advanced Prostate Cancer and Its Association With Clinical Parameters
12天前
已完结
Prognostic [68Ga]Ga‐PSMA‐11 PET Biomarkers for [177Lu]Lu‐PSMA Radioligand Therapy in Metastatic Castrate‐Resistant Prostate Cancer (Asian Population Study)
26天前
已完结
The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer
26天前
已完结
Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study
26天前
已完结
Effect of bone marrow disease on hematologic toxicity and response to [177Lu]Lu-PSMA-617 therapy: insights from PSMA-PET/CT imaging
26天前
已完结
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
26天前
已完结
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
26天前
已完结
皖公网安备34019202002308
